PYXS - Pyxis Oncology, Inc. Average Forecast Price

Pyxis Oncology, Inc. (PYXS) is implementing robotic systems to accelerate molecule selection during drug development. The stock's price chart is driven by a team of top biologists striving for scientific breakthroughs supported by R&D. The current metric stands at 8.18. However, the company faces a capital shortage, as antibody trial costs are being funded by existing cash reserves.

PYXS (Pyxis) Price Target Chart history from 07/04/2022 to 11/11/2026

Metric breakdowns and analytics for Pyxis Oncology, Inc. (PYXS)

- share price and expert price forecast:

Quote Chart pyxisoncology.com|PYXS - Consensus Target

- market capitalization statistics:

Market Value Pyxis|PYXS - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Equity per Share Pyxis Oncology|PYXS - Company Book Value|Market Capitalization to Book Value pyxisoncology.com|PYXS - Aggregate Company Assets

- business debt structure and liquidity details:

- net income and valuation multiples indicators:

PYXS - Company Net Income|Expected Net Profit Pyxis Oncology, Inc.|PYXS - P/E Multiple|Forward Price to Earnings Multiple pyxisoncology.com|PYXS - Price/Earnings to Growth Multiple|Company Value to EBITDA Pyxis|PYXS - Operating profit before deduction of amortization|Earnings per share for the trailing year Pyxis Oncology|PYXS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months pyxisoncology.com|PYXS - Earnings per share growth in current year|Expected earnings per share growth for next year Pyxis Oncology, Inc.

General company analysis:PYXS (Pyxis Oncology Inc.)

Mass-produced product of Pyxis Oncology Inc.

This indicator aggregates target share prices from leading analysts, allowing investors to assess the asset's market potential and timely identify trend reversals. By analyzing the average price targets from investment banks, one can determine capital readiness to purchase Pyxis Oncology, Inc. (PYXS), which is particularly critical when assessing the logistics risks of complex immunotherapeutic drugs and strict adherence to pharmaceutical delivery protocols.

Competitors of Pyxis Oncology, Inc.